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43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects
with CF who have the G551D-CFTR mutation
A.L. Quittner1, B. Ramsey2, Q. Dong3, K. Yen3, J.S. Elborn4. 1University of
Miami, Coral Gables, United States; 2Seattle Children’s Hospital, Seattle, United
States; 3Vertex Pharmaceuticals Incorporated, Cambridge, United States; 4Belfast
Cystic Fibrosis Centre, Belfast, United Kingdom
Objectives: Two Phase 3 studies were conducted to evaluate the effect of ivacaftor
in CF subjects with a G551D mutation. Change in Cystic Fibrosis Questionnaire-
revised (CFQ-R) scores was evaluated in both studies.
Methods: Both were randomized, double-blind, placebo-controlled studies. Subjects
received placebo or ivacaftor 150mg q12h for 48 weeks in addition to prescribed
therapies. In STRIVE, 161 subjects 12 years were dosed. In ENVISION, 52
subjects 6−11 years were dosed. The CFQ-R is a patient-reported outcome measure
with multiple domains each scored on a 100-point scale. Higher numbers indicate
fewer symptoms. In the respiratory domain, a difference of at least 4 points is
considered the minimal clinically important difference (MCID). MCIDs for other
domains have not been established.
Results: The treatment difference in the mean pooled CFQ-R Respiratory Symp-
toms scores for ivacaftor vs. placebo through Week 48 was 8.6 points (P < 0.0001)
in STRIVE and 5.1 points (P = 0.1354) in ENVISION. Differences between groups
were detected by Day 15 in both studies and were maintained at subsequent visits
in STRIVE. In STRIVE, the treatment difference for ivacaftor was 4.4 points
(P = 0.0055) for the Physical Functioning scale, 4.3 points (P = 0.0026) for Social
Functioning scale, 3.3 points (P = 0.0021) for Eating Disturbances scale, and 3.3
points (P = 0.0419) for Treatment Burden scale.
Conclusions: Both studies demonstrated clinically meaningful improvements in
respiratory symptoms that were rapid, durable, and of comparable magnitude. There
were statistically signiﬁcant improvements in other domains, though the MCID for
those domains has not been established.
Sponsored by Vertex.
44 Pulmonary exacerbations in a Phase 3 trial of ivacaftor in subjects
with cystic ﬁbrosis who have the G551D-CFTR mutation
M. Griese1, B. Ramsey2, S. Rodriguez3, K. Yen3, J.S. Elborn4, on behalf of the
VX08–770–102 Study Group. 1Haunersches Kinderspital, Munich, Germany;
2Seattle Children’s Hospital, Seattle, United States; 3Vertex Pharmaceuticals
Incorporated, Cambridge, United States; 4Belfast Cystic Fibrosis Centre, Belfast,
United Kingdom
Objectives: Pulmonary exacerbations have been associated with a worsening
decline in lung function and are a major cause of morbidity in CF. Pulmonary
exacerbations were evaluated in a Phase 3 study of ivacaftor (STRIVE) in subjects
with CF who have a G551D-CFTR mutation.
Methods: This was a randomized, double-blind, placebo-controlled, multicenter
study in which subjects received placebo or ivacaftor 150mg q12h for 48 weeks in
addition to their prescribed therapies. 161 subjects with CF who were 12 years
of age and had percent predicted FEV1 at screening of 40%-90% were dosed.
Pulmonary exacerbations were identiﬁed by modiﬁed Fuchs’ criteria.
Results: The pulmonary exacerbation-free rate was 67% in the ivacaftor group
compared to 41% in the placebo group from baseline through Week 48. The rate
of pulmonary exacerbations through 48 weeks in the ivacaftor group was less than
half that of the placebo group (rate ratio = 0.426; P = 0.0003). There was a 55%
reduction in risk of a pulmonary exacerbation for subjects in the ivacaftor group
relative to subjects in the placebo group through Week 48 (hazard ratio: 0.455;
P = 0.0012). The mean number of days with pulmonary exacerbation, adjusted for
time on study, was signiﬁcantly less in the ivacaftor group than in the placebo group
through Week 48 (13.5 versus 36.7 days; P = 0.0007). The most commonly reported
adverse events were respiratory in nature. The incidence of adverse events through
Week 48 was similar between groups.
Conclusions: Treatment with ivacaftor resulted in marked improvement in the risk
of experiencing a pulmonary exacerbation, as well as the frequency and duration
of pulmonary exacerbations.
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45 Drug–drug interactions between ivacaftor and midazolam or
rosiglitazone in healthy volunteers
Y. Chen1, J. Huang1, C.L. Ordon˜ez1, J. Zhang1, L. Mahnke1, J. Zha1. 1Vertex
Pharmaceuticals Incorporated, Cambridge, United States
Objectives: Ivacaftor, a selective potentiator of cystic ﬁbrosis transmembrane
conductance regulator (CFTR), demonstrated substantial, durable improvements
in lung function, respiratory symptoms and weight gain, as well as sustained
improvements in CFTR function in subjects with CF. In vitro studies demonstrated
that ivacaftor and its metabolite M1 were reversible inhibitors of CYP2C8 and weak
inhibitors of CYP3A. Therefore, ivacaftor may have drug–drug interactions with
CYP3A (e.g., midazolam) or CYP2C8 (e.g., rosiglitazone).
Methods: A single-center, open-label, 2-period, 1-sequence crossover study was
conducted with 24 healthy subjects between 18 and 55 years of age. The effects of
co-administration of steady-state ivacaftor on the pharmacokinetic parameters of:
1. a single dose of the CYP3A substrate midazolam and its metabolite 1′-hydroxy-
midazolam; and
2. a single dose of the CYP2C8 substrate rosiglitazone, were evaluated in this study.
Results: Co-administration of ivacaftor at steady-state slightly increased the mida-
zolam Cmax and AUC0−∞ by 1.4-fold [CI: 1.26, 1.52] and 1.5-fold [CI: 1.39, 1.69],
respectively. Midazolam metabolite 1′-hydroxymidazolam Cmax and AUC0−∞ were
similar with and without ivacaftor (0.92-fold (0.82, 1.03) and 1.10-fold (0.98,
1.25), respectively). Co-administration of ivacaftor at steady-state did not affect
the exposure of a CYP2C8 substrate rosiglitazone.
Conclusions: Ivacaftor is a weak CYP3A inhibitor. Caution is warranted when a
sensitive CYP3A substrate with narrow therapeutic index is co-administered with
ivacaftor. No dose adjustment is required when ivacaftor is co-administered with
CYP2C8 substrates.
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46 Hyperpolarized Gas MRI of ivacaftor therapy in subjects with
cystic ﬁbrosis who have the G551D-CFTR mutation
T. Altes1, M.A. Johnson2, G.W. Miller1, J.P. Mugler1, L. Flors1, J. Mata1,
C.L. Salinas1, N. Tustison1, T. Song2, K. Yen2, D. Froh1, M.C. Botﬁeld2.
1University of Virginia, Department of Radiology and Medical Imaging,
Charlottesville, United States; 2Vertex Pharmaceuticals Incorporated, Cambridge,
United States
Objectives: Hyperpolarized Gas MRI (HG-MRI) allows direct, high-resolution
imaging of certain non-radioactive isotopes of noble gases, such as He-3. Images
from patients with CF show numerous “ventilation defects” − areas of the lung
into which inhaled gas does not ﬂow due to airway obstruction. Ventilation defects
correlate with disease severity. Ivacaftor improves FEV1 in patients with CF who
have the G551D-CFTR mutation.
Methods: This single-center, Phase 2, single-blind, placebo-controlled study evalu-
ated the effects of ivacaftor on ventilation as revealed by HG-MRI in 8 subjects with
CF who have the G551D-CFTR mutation and to assess the utility of HG-MRI as a
biomarker of lung disease. Subjects were required to have FEV1 40% predicted
to enroll. Subjects received ivacaftor 150mg q12h for 4w and placebo for a total
of 4w.
Results: HG-MRI revealed ventilation defects at baseline in all subjects, including
those with FEV1 >90% predicted. 28d treatment with ivacaftor led to a substantial
reduction in total ventilation defects [8.20% as determined by human reader (HR)
(P = 0.0547) and 12.81% by computer algorithm (CA) (P = 0.0078)] and total defect
volume [0.48 L as determined by HR (P = 0.0313) and 0.68 L by CA (P = 0.0078)]
as assessed by HG-MRI. This correlated with an increase in FEV1% predicted of
12.8% (P = 0.0078).
Conclusions: HG-MRI could provide a novel endpoint in clinical trials of CF, one
that both corroborates traditional pulmonary function testing and provides unique
information, including absolute quantiﬁcation of disease burden, information on
burden in each lung or lobe, and assessment of burden in patients with relatively
normal spirometry.
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